Evidence map›Paper›PMID 35846880›Full record

ArticlePeerJ2022

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.

Wei Peng, Wei Tang, Jian-Di Li, Rong-Quan He, Jia-Yuan Luo, Zu-Xuan Chen, Jiang-Hui Zeng, Xiao-Hua Hu, Jin-Cai Zhong, Yang Li and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Wei Peng *Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Wei Tang *Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Jian-Di LiDepartment of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Rong-Quan HeDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jia-Yuan LuoDepartment of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zu-Xuan ChenDepartment of Medical Oncology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jiang-Hui ZengDepartment of Clinical Laboratory, The Third Affiliated Hospital of Guangxi Medical University/Nanning Second People's Hospital, Nanning, Guangxi, China.
Xiao-Hua HuDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jin-Cai ZhongDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yang LiDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Fu-Chao MaDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Tian-Yi XieDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Su-Ning HuangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Lian-Ying GeDepartment of Endoscopy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Guangxi Medical University · CNFirst Affiliated Hospital of GuangXi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer and lacks effective biomarkers. This study seeks to unravel the expression status and the prospective transcriptional mechanisms of EZH1/EZH2 in TNBC tissue samples. Moreover, another objective of this study is to reveal the prognostic molecular signatures for risk stratification in TNBC patients. Methods: To determine the expression status of EZH1/EZH2 in TNBC tissue samples, microarray analysis and immunohistochemistry were performed on in house breast cancer tissue samples. External mRNA expression matrices were used to verify its expression patterns. Furthermore, the prospective transcriptional mechanisms of EZH1/EZH2 in TNBC were explored by performing differential expression analysis, co-expression analysis, and chromatin immunoprecipitation sequencing analysis. Kaplan-Meier survival analysis and univariate Cox regression analysis were utilized to detect the prognostic molecular signatures in TNBC patients. Nomogram and time-dependent receiver operating characteristic curves were plotted to predict the risk stratification ability of the prognostic-signatures-based Cox model. Results: In-house TMAs (66 TNBC Conclusion: EZH1 downregulation may be a key modulator in the progression of TNBC through negative transcriptional regulation by targeting

Indexed as

Triple Negative Breast NeoplasmsCell Cycle ProteinsDown-RegulationHumansMembrane ProteinsPolycomb Repressive Complex 2PrognosisProspective StudiesProtein Serine-Threonine KinasesProtein-Tyrosine KinasesRNA, MessengerCell Cycle ProteinsEZH1 protein, humanMembrane ProteinsPKMYT1 protein, humanPolycomb Repressive Complex 2Protein Serine-Threonine KinasesProtein-Tyrosine KinasesRNA, MessengerEZH1Molecular approachesTranscriptional regulationTriple-negative breast cancer

Identifiers

PMID35846880
PMCPMC9285492
OpenAlexW4285089982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.